Replies to post #445751 on Anavex Life Sciences Corp (AVXL)

[bas2020]

It's only disappointing that randomization and "placebo-effect" skewed the results. Otherwise, it's clear the drug is safe and effective... as we'll soon see when all the data are provided. The FDA won't have any problem approving blarcamesine for Rett.

[crescentmotor]

With the disappointing Excellence results, the company has just freed up a significant amount of capital

Just the opposite of what should happen given the near-term loss of a Rett revenues opportunity. AVXL should batten down discretionary spending and preserve all the liquidity it can in the face of uncertainty regarding regulatory approval for AD. After waiting years to start trials in new indications, the prudent decision right now is to keep them on hold during 2024 and minimize cash outflow.